According to the World Health Organization, the world's seasonal flu vaccine production capacity will double by 2015 to 1.7 billion doses. And that production could swell 5.4 billion doses for a
The World Health Organization appears to be getting on top of the complex supply/demand dynamic of pandemic vaccine readiness--despite reports to the contrary. WHO said late last week in News Tonight
Australian scientist Barry Marshall continues to make hay with the cancer-making stomach bacterium that won him a Nobel Prize. He's planning to use the bug in a drinkable flu vaccine that's slated to
BiondVax Pharmaceuticals has completed its first Phase II trial of Multimeric-001, its universal flu vaccine, and the results have spurred the company to begin planning its next test of the vaccine.
San Francisco-based Vaxart has started dosing patients in its first Phase I trial using its oral vaccine platform. The study uses an H5N1 flu vaccine, but the platform, if effective, could be used
The FDA has approved an sBLA for Fluzone Intradermal--a seasonal flu vaccine that features a tiny, ultra-fine needle that's just one an a half millimeters long, or 90 percent shorter than the typical
Just a month after granting major contracts to VaxInnate and Novavax, BARDA is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir. The drug is a long acting
"VaxInnate: We're fast, cheap and easy," jokes CSO Alan Shaw (pictured, left). And that's just what the HHS likes about the company. Last month the agency granted the Cranbury,...
Although DMXAA was developed to fight cancer, researchers have found the anti-tumor agent has promising results in flu vaccines via an interferon response. In a study published in the Journal of
The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares